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ABSTRACT 
From November 2012 to July 2014, brentuximab vedotin was available in Italy for patients 
with relapsed systemic anaplastic large cell lymphoma outside a clinical trial context 
according to the national law 648/96. A large Italian observational retrospective study was 
conducted on the use of brentuximab vedotin in the everyday clinical practice to check if 
clinical trial results are confirmed even in a real life context. Primary endpoint was the best 
response; secondary endpoints were the overall response rate at the end of the treatment, 
duration of response, survival and the safety profile. A total of 40 heavily pretreated 
patients were enrolled. Best response was observed after a median of 4 cycles in 77.5%: 
globally, 47.5% patients obtained a complete response, 64.2% in the elderly subset. 
Overall response rate was 62.5%. At the latest follow up 15/18 patients are still in 
complete response (3 with consolidative procedure). Progression free survival was 39.1% 
at 24 months and disease free survival 54% at 24 months (median not reached). 
Particularly, all the long term responders were aged <30 years at first infusion. The 
treatment was well tolerated even in this real life context and no death has been linked to 
drug toxicity. Brentuximab vedotin induces clinical responses quite rapidly, i.e. within the 
first 4 cycles in most responder patients, thus permitting the timely application of the 
transplantation phase. For patients ineligible for transplant or for who transplant failed, 
brentuximab vedotin may represent a feasible effective therapeutic option in everyday 
clinical practice. 
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Introduction 
 
Approximately 40% to 65% of patients with systemic anaplastic large-cell lymphoma 
(sALCL) develop recurrent disease after front-line therapy.1 Historically, at relapse the 
disease is resistant to conventional multiagent chemotherapy regimens, and there is no 
established standard of care. High-dose therapy and autologous stem cell transplantation 
(ASCT) may result in long-term remission in 30% to 40% of patients, but the benefit is 
limited to patients with chemotherapy-sensitive disease.2-6  
Given that most patients with relapsed and refractory (R/R) sALCL are scheduled to 
undergo a highly toxic high-dose chemotherapy regimen, any strategy aimed at achieving 
a minimal disease status, specifically a positron emission tomography (PET)-negative 
status before ASCT, without severe toxicity would represent a major advance in the overall 
management of these patients. Furthermore, although the role of ASCT, the outcomes 
remain poor in those with primary chemorefractory disease, where long-term survival 
rarely exceeds 15-17%.1 In fact, disease recurrence still remains the principal cause of 
ASCT failure, and early disease progression after transplant, i.e. within 6 months from 
high-dose conditioning, emerges as the most important predictor of unfavorable outcome. 
No standard treatment options exist for patients showing disease relapse after ASCT or for 
patients not eligible for ASCT. In fact, while allogeneic stem cell transplantation (alloSCT) 
may induce a long-term progression-free survival (PFS) in a fraction of patients, only a few 
are candidates for this procedure, mainly as a result of unsatisfactory pre-transplant 
cytoreduction and substantial risk of morbidity due to the heavy load of previous therapies. 
Under this light, the optimization of the outcomes obtained with high-dose regimens and 
ASCT still remains a current strategic priority, in order to offer the best chance of cure for 
the largest fraction of patients with R/R disease. 
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Brentuximab vedotin (BV) is an antibody-drug conjugates targeting CD30 which 
may represent the optimal candidate among the new developed agents for the treatment 
of R/R  sALCL.7 In fact, sALCL is characterized by the expression of CD30. In the initial 
phase 1 study of BV in patients with CD30+ lymphoid diseases, both the 2 sALCL patients 
achieved a complete response (CR).7 The favorable activity of this agent in R/R sALCL 
was clearly documented by Pro et al in a phase 2 study involving 58 patients: 86% 
obtained a response, which was a CR in 57% of cases.8 Median PFS for these patients 
was 13.3 months, and the median overall survival (OS) was not reached (estimation is 
64% at 4 years). The same relevant proportion of CR in this subset of patients also 
emerges from the data collected by Zinzani et al regarding the BV Named Patient Program 
(NPP) experiences across Europe.9,11,15-17 
This high response rate is important not only in pretreated patients showing a poor 
prognosis, but also in first-line R/R patients because a CR obtained before transplant is 
one of the stronger predictors for long-term survival.10 BV can represent an optimal 
therapeutic option as a bridge to both ASCT and alloSCT program in patients achieving a 
suboptimal response after salvage treatment.11,12 Recent updates on the pivotal study 
have shown that BV can induce long lasting CR in sALCL pretreated cases either without 
additional consolidation therapies, suggesting that BV may be curative for some 
patients.13,14 The pooled overall response rate (ORR) and CR rate reported for R/R sALCL 
patients (globally 46) in NPP cohorts were 69.5% for both rates.9,11,15-17  
After accelerated approval by US Food and Drug Administration, eligible patients in 
Italy were granted early access through a NPP. After the closure of NPP, between 2012 
BV was available in Italy for patients with R/R sALCL, based on a local disposition of the 
Italian Drug Agency (AIFA) issued according to a national law (Law 648/96: “medicinal 
products that are provided free of charge on the national health service”): a boundary zone 
7 
 
in the passage from clinical trials to marketing and free use phases where patients can be 
treated in any case.  
On the basis of our previous explorative study,18 a large Italian observational 
retrospective study was conducted on the use of BV in R/R sALCL patients in the 
everyday clinical practice to check if clinical trial results are confirmed even in a real life 
context. 
 
Methods 
An observational retrospective study was conducted among patients with sALCL 
treated from November 2012 to July 2014 with BV in 38 Italian centers outside of clinical 
trials, according to the national law no. 648/96.19 The study was approved by our 
institutional board (Azienda Ospedaliera di Bologna, Policlinico S.Orsola-Malpighi, 
coordinating center) and by all involved Ethical Committees and registered in the Italian 
Registry of Observational Studies. All participants gave written informed consent in 
accordance with the Declaration of Helsinki. A shared database was used after the 
approval of all the co-investigators and variables were strictly defined to avoid bias in 
reporting data.19 We obtained a special permission (for scientific purpose) from our Ethical 
Committee to collect even data of patients who were deceased or lost to follow up.  
BV is administered as a 30-minute infusion of at the dose of 1.8 mg/kg of body 
weight every 3 weeks for a maximum of 16 cycles. Dose reduction to 1.2 mg/kg is 
recommended in case of grade 3 toxicity and the treatment has to be interrupted in case of 
grade 4 toxicity.  
The primary endpoint of the study was the best response achieved during BV 
therapy; secondary endpoints were the ORR at the end of the treatment, duration of 
response (DoR), OS, PFS, disease free survival (DFS), and the drug safety and 
tolerability. Duration of therapy was defined as the number of cycle performed. 
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Effectiveness was also evaluated through the occurrence of long term responder (LTR) 
patients, defined as patients who have response (CR or partial response [PR]) duration 
≥12 months. Response is assessed by PET/CT scan after cycle 4, 8, 12 and at drug 
discontinuation by each investigator using the International Working Group revised 
response criteria for malignant lymphoma.20 Safety and tolerability were evaluated by 
recording incidence, severity, and type of any adverse event (AE) according to the 
National Cancer Institute Common Terminology Criteria for AEs v4.0.  
OS was defined as the time from initiation of therapy to death from any cause and 
was censored at the date of the last available follow up. PFS was measured from initiation 
of therapy to progression, relapse, or death from any cause and was censored at the date 
of the last available follow up. DFS was calculated for CR patients from the first 
documentation of response to the date of relapse or death due to lymphoma or acute 
toxicity of treatment. DoR was calculated from the first objective tumor response (CR or 
PR) to first documentation of progression or death.20 Lost to follow up patients (N=2). were 
censored at the latest available date. 
Demographics and patients’ characteristics as well as AEs were summarized by 
descriptive statistics. Survival functions were estimated by using the Kaplan-Meier method 
and were compared using log-rank test. Statistical analyses were performed with Stata 11 
(StataCorp LP, TX) and p values were set at 0.05. 
 
Results 
 Of the estimated 40 patients who received BV under the Law 648/96, all 
participated in this observational study. All had histologically confirmed CD30+ disease. 
The median age at BV was 47 years (range, 17-80 years) with 14 (35.0%) elderly (age> 
60 years) patients; 28 were males and 12 were females. Eleven (27.5%) had systemic 
symptoms at baseline (Table 1). 
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The median number of prior lymphoma-related systemic regimens was 2 (range, 2-
10) including high dose chemotherapy and autologous stem cell transplantation (ASCT) (in 
13, 32.5% of the patients). Eight patients (20%) had received prior radiation therapy. 
Eighteen were anaplastic lymphoma kinase negative (ALK+) and 22 anaplastic lymphoma 
kinase positive (ALK-) status. For each patient the status after both frontline therapy and 
most recent therapy was collected:  24 (60%) patients had disease that was refractory to 
frontline therapy and 25 patients (62.5%) had disease that was refractory to last therapy 
before BV.  
Response to treatment  
Best response was observed after a median of 4 cycles in 31 (77.5%) patients: 19 
(47.5%) obtained a CR and 12 (30%) achieved a partial response (PR). Overall responses 
rate at the end of the treatment was 62.5% (25 patients) represented by 18 (45%) CR and 
7 (17.5%) PR; among the remaining patients, one had stable disease (SD), and 14 
patients showed progression of disease (PD), respectively. 
The best response rate was higher in the elderly subset (>60 years): 9 (64.3%) CR 
and 3 (21.4%) PR with an overall response rate of 85.7%. Four patients who were in CR at 
first restaging relapsed during further BV courses; 2 patients who were in PR at first 
restaging converted to CR status after the 4 subsequent infusions.  
All patients who were in SD or PD at first restaging did not improve their status at 
the end of therapy. The median number of cycles administered was 8 (range 1-16). 
With a median follow up of 18 months global OS was 56.9% at 24 months (Figure 1) and 
median not reached yet. PFS at 24 months was 39.1%, median achieved at 12.5 months 
(Figure 2). DFS was 54% at 24 months (Figure 3); 4 out of 19 (21%) CR patients relapsed 
and 15 patients were in continuous CR (CCR) at the last follow up with a median DoR of 
12 months (range, 9-24 months). After controlling for confounding variables, no differences 
in any time to point endpoints between ALK- and ALK+ patients were observed. 
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Among the CRs, 3 patients had consolidation with transplant (1 ASCT and 2 
alloSCT). Currently, 15 patients are still in CR and, in particular, the 3 with consolidative 
procedure; among elderly patients, 6 out of 9 (66.7%) patients are still in CCR without any 
consolidative procedure after a median of 14 months.  There are 5 LTR patients and all of 
them are still in CCR at the last available follow up. To note,  they were all aged <35 years 
at BV therapy and only 1 of them had a subsequent consolidative transplant. At the latest 
follow-up, 27 (67.5%) patients were alive and 13 deceased (11 due to lymphoma, 2 for 
complications after alloSCT: one for respiratory insufficiency related to graft-versus-host-
disease and 1 for pneumonia). 
Safety 
All patients who received at least one BV infusion were included in the safety 
analysis. In general, the treatment was well tolerated and the toxicity profile was very 
similar to the previously published data. Twelve patients had at least one toxicity. All 
hematologic toxicities but one were grade 1-2. In fact, we registered a grade 3 
neutropenia. The extra-hematologic side effects were mostly represented by peripheral 
sensorial neurological toxicity (15/20) and, among them, 3 were grade 3. The other AEs 
were by nausea grade 1-2 (two patients), erythema grade 2 (two patients), hyposthenia 
grade 2 (one patient). Neurological toxicity always reversed completely after end of 
treatment. No long-term toxicity related to BV was observed during the follow-up period, 
even in patients later subjected to transplant consolidation. 
  
Discussion 
This retrospective large multicenter Italian study on 40 patients with R/R sALCL 
treated with BV outside a clinical trial represents the largest ever reported in a real world 
context. Our results are in accordance to the pivotal phase II study and its updates and to 
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the other national experience studies with an ORR of 77.5% and a CR rate of 47.5% in 
terms of best response.8,9,11,14-18 
In addition, we extrapolate some interesting consideration about the role of BV in 
everyday clinical practice. First, both the best response rate and ORR were higher in the 
elderly setting: 85.7% vs 77.5% and 64.3% vs 62.5%, respectively. 
To be in CR after 4 cycles is confirmed very important for classifying the patient as 
a real good responder; at the same time, the right number of cycles to be performed for 
evaluating the potential consolidation with transplant (in the major part allogeneic 
transplant) or the continuation with BV until the cycle 16 remains an open issue, mainly 
because in case of CR the choice between the two options is at the physician discretion.   
According to the recent update by Pro et al. on the pivotal phase II study, the 5-year PFS 
was 68% in CR patients submitted to alloSCT versus 47% in patients who continued BV 
treatment even though they had obtained CR after the first 4 cycles.8,14 In this update the 
authors reported that 27.6% of the whole study population has achieved long-term 
remission exceeding 5 years in response to single agent BV without any additional 
anticancer therapy, other than transplant. In our study the estimated DFS at 2 years was 
54% and 15 patients (37.5%) are in CCR with a median DoR of 12 months (range 9-24 
months). As only 3/15 patients had transplant consolidation, comparison between them 
and patients who did not received SCT procedure was not possible.  Thus, also in the real 
life experience as in the in the pivotal study, DoR and DFS indicate that, among R/R 
sALCL, a substantial subset of patients who obtained CR with single agent BV either 
obtained a long-term disease control and may potentially be cured. An important question 
remains unclear: among the patients in CR, which may benefit from the transplant 
consolidation? In our series there are 5 LTR patients and all of them are still in CCR at the 
latest follow-up and, in particular, only 1 with a consolidative alloSCT procedure. Update 
on pivotal study and our data could indicate that it is possible to obtain long disease 
12 
 
control also without transplant consolidation with the real chance to cure a subset of R/R 
sALCL only with BV.14     Physicians are still divided on whether or not offer a consolidative 
transplant to CR patients as solid clinical trial data are lacking on this issue. A large, well-
designed randomized control study is needed, but ALCL is so rare that we are unlikely to 
ever have a definitive answer. 
Differences in survival outcomes between ALK+ and ALK- patients have been often 
reported: no statistical significance in our sample was observed between the two 
subgroups.21  
Our study indicated that for patients who obtained a SD or PD after 4 cycles of BV 
the potential conversion rate to PR or CR with further administrations is close to zero. The 
final message is that when patients show SD or PD at first restaging, they have to be 
shifted rapidly to another treatment. On the other hand, for patients who achieved PR after 
first restaging it could be important to continue the treatment: in our series 2/12 (16.7%) 
patients showed a conversion from PR to CR status.  
In conclusion, the results of this large retrospective study on 40 R/R sALCL in the 
daily practice support the efficacy of single agent BV with manageable toxicity without 
evidence of cumulative toxic effects with previous regimens. We acknowledge that this 
kind of reports carry potential bias as the lacking of predictable and calculated sample size 
and the risk of toxicity underreporting. ALCL represents approximately 2% to 3% of all 
lymphoid neoplasms, thus it is a very rare disease. The phase II study who lead to an FDA 
accelerated approval of BV enrolled globally 58 patients, thus 40 ALCL patients from a 
single nation is a substantial sample related to this pathology. However, we could not 
analyze prognostic features due to the small sample and we reported the raw observed 
data. Observational studies may better identify clinically important AEs when compared 
with randomized controlled trials, for several reasons. Those reasons include longer 
follow-up times, the inclusion of patients with concomitant illnesses who may be more 
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likely to experience drug interactions or other side effects and to detect infrequent or rare 
complications. Regarding the retrospective nature of this specific study, AIFA has a strict 
monitoring on drugs prescribed under the law 648/96 and physicians have to report any 
AE occurring during treatment: thus, all the safety data are already in the patients’ chart at 
the time our retrospective study starts.  
In particular, our report confirms the activity in elderly patients, the duration of the 
clinical response independently by the transplant consolidation, and the relevance of the 
CR status after 4 cycles in term of final response. BV is the first drug which led to a drastic 
management change in ALCL, entailing an ORR of 80%. Next research efforts could be 
aimed at developing combination regimens with BV to reach the 100% of response in R/R 
ALCL patients. 
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Table 1: Patient demographics and characteristics at baseline. 
 
Total population, N 40 
ALK+ 
ALK- 
22 
18 
Median age, years (range) 51.4 (22.6-80.7) 
Median time from diagnosis-BV, years 
(range) 
2 (1-16) 
Male, N (%) 28 (70.0) 
Stage, N (%) 
- I/II  
- III 
- IV 
 
9 (22.5) 
5 (12.5) 
26 (65.0) 
Systemic symptoms, N (%) 11 (27.5) 
- Refractory to most recent therapy, N (%) 
- Refractory to first line therapy, N (%) 
24 (60.0) 
25 (62.5) 
Median number of previous therapies (range) 2 (2-10) 
Prior autologous stem cell transplant, N (%) 13 (32.5) 
Prior radiotherapy, N (%) 8 (20) 
ALK: anaplastic lymphoma kinase; BV: brentuximab vedotin; ECOG: Eastern Cooperative 
Oncology Group. 
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Figure Legends 
 
Figure 1: Overall survival. 
Figure 2: Progression free survival. 
Figure 3: Disease free survival. 
 
 
 
 
 



